Training Example: Pfizer Inc. – Review the Data, Give Your Score & Compare to the Real AI Evaluation

[IMG: bladder cancer banner]
[H1] What to know about bladder cancer
Recognizing early symptoms of bladdercancer can make a difference. Learn more
[IMG: Aerial photo of a large office complex at a highway intersection near the coast]
[H4] Pfizer’s New San Diego R&D Hub Accelerates the Next Wave of Cancer Innovation
New state-of-the-art campus is designed to turn scientific ambition into breakthroughs for people with cancer.Learn all about itPfizer’s New San Diego R&D Hub Accelerates the Next Wave of Cancer Innovation Podcast Highlights Pfizer Foundation’s Mission to Improve Breast Cancer OutcomesNot Quite Out of the Woods: Risk for Lyme Disease Prevails in Suburban Environments What is Non-Muscle Invasive Bladder Cancer?European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors | 05.13.2026
Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance | 05.05.2026
Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma | 04.29.2026
[H3] Products
Every product is the result of 1,500 scientists overseeing more than 500,000 lab tests and over 36 clinical trials before the first prescription.
[H3] Pfizer RxPathways
Pfizer RxPathways connects eligible patients to a range of assistance programs that offer insurance support, co-pay help, and medicines for free or at a savings.
Explore RxPathways
DetailsPipeline Snapshot as of May 5, 202600Phase 100Phase 200Phase 300Registration00
TotalExplore the Product PipelineDownload Complete Pipeline PDF
[IMG: pipeline animated GIF lines loading in 3D]
Areas of Focus

[H4] Revolutionary medicines enable us to enrich and extend life for people living with all types of diseases.
[IMG: Internal medicine graphical thumbnail portrait image 2]
[H5]
Internal Medicine
View All Internal Medicine
We’re developing therapies to treat, slow, or prevent disease progression and improve the quality of life for patients with obesity, type 2 diabetes, and cardiovascular and kidney diseases.
[IMG: Inflammation and Immunology graphical thumbnail portrait image 3]
[H5]
Inflammation & Immunology
View All Inflammation & Immunology
We look for treatments that provide more than just symptom relief, in order to address the root cause of chronic inflammatory diseases at a molecular level
[IMG: Vaccine graphical thumbnail portrait image 4]
[H5]
Vaccines
View All Vaccines
Vaccines are the single most important innovation in the science of health to significantly reduce the threat of diseases that were once widespread and oftentimes fatal. Vaccines Milestones Pipeline & Clinical Trials
[IMG: Oncology graphical thumbnail portrait image 5]
[H5]
Oncology
View All Oncology
Cancer treatment needs to be transformed across the entire landscape to significantly improve the lives of cancer patients worldwide.OncologyBiology into medicineAdvocacy Global Impact
Button previous
Button next
[H2] About
[H4] Starting with Charles Pfizer inventing an almond-flavored antiparasite medicine in 1849, our people have always been innovators and trailblazers, committed to finding the next cure.
Learn More About Us
Details
[H4] An Accord for a Healthier World
Where people live shouldn’t impact the quality of their healthcare and income shouldn’t determine health outcomes.
Learn More About The Accord
Details
[IMG: Accord for healthier world globe]
[IMG: Accord for healthier world globe]
[H3] Sign Up for communications from Pfizer
Receive the latest news from Pfizer in our monthly The Breakthrough newsletter and email alerts on a variety of topics.
Sign up now
Details

[H2] Our Pipeline:Potential Breakthroughs in the Making
We're in relentless pursuit of medicines and vaccines that will benefit patients around the world. Our ambitions are big and our product pipeline has never been stronger.Guided ExplorationComprehensive ListDownloadable PDF
Key 2026 Catalysts
Pipeline as of May 5, 2026CandidatesAdjust filters orReset all to view products
[H1] Explore the Product Pipeline
Take a deep dive into the investigational medicines and vaccines we’re working on.Updated as of May 5, 2026.LeaveHelpPhase 1Phase 2Phase 3RegistrationPhase 1Phase 2Phase 3RegistrationAre you sure you want to leave the product pipeline?StayLeaveDiscoverAn immersive look at all the medicines and vaccines we’re currently researching. The dock takes you through four filters, like a guided tour that allows you to explore the full pipeline.FilterYou can customize how you view our Product Pipeline using the filters in the dock. Hit ‘all filters’ to make your selections and get a list of results. Filtering the pipeline brings it into closer focus for people who know what they’re looking for.SearchKnow exactly what you’re looking for? You can type a product or term directly into the Search box.LearnThis section defines all the terms you’ll see throughout the Pfizer Product Pipeline. You can tap the (i) wherever you see it in the experience to be brought to this glossary.End Tutorial Don't display tutorial againCloseDevelopment Phase
BackGlossaryDevelopment PhaseClinical trials are divided into four sequential phases.
Phase 1 studies help scientists understand the safety and correct dosing of an investigational medicine or vaccine.
Phase 2 studies gather more information about safety and begin to understand how well a study treatment or vaccine works (efficacy).
Phase 3 studies focus on safety, efficacy, and dosing in preparation for regulatory approval. Phase 4—which is not reflected in the Product Pipeline--continues to monitor and collect data after a medicine or vaccine has been approved for use.Phase 1Phase 1 asks the questions “Is an investigational drug or vaccine safe?” and “What is the correct dose?” Typically, these studies are done with a small group of healthy volunteers.
But for some investigational therapies, such as those for cancer, the study is done with patients who have the condition the drug is targeted to treat.
In this stage, somewhat limited information is available about an investigational drug or vaccine. Scientists may still be gathering information about which specific disease to target with the investigational medicine.
Industry-wide, only 10% of Phase 1 candidates will make it to approval. On average, it takes 10 years to move from Phase 1 to regulatory approval.Phase 2Phase 2 asks the questions “Does this investigational medicine or vaccine work in the disease that’s targeted?” and “Are there any side effects that may occur?” These studies are done with a larger group of people—as many as several hundred participants—who have the condition the drug or vaccine is intended to treat. These studies last several months to a few years.
Phase 2 is often considered the steepest hurdle in clinical development. Some 70% of Phase 2 candidates industry-wide fail in this stage.Phase 3Phase 3 studies ask “How safe and effective the investigational drug or vaccine is for people with the condition and also sees if it works compared to a placebo or what else is currently available. Phase 3 studies seek to find out how safe and effective the investigational drug or vaccine is for people with the condition, and also if it works compared to a placebo or something else currently available. This phase usually signifies when an investigational medicine or vaccine may be two to three years from approval, subject to clinical trial and regulatory success.RegistrationAfter Phase 3, if the clinical trial data supports it, an extensive data package is submitted to the U.S. Food and Drug Administration (FDA) and other regulatory authorities for review. This review process typically takes a year.Show AllPhase 1Phase 2Phase 3RegistrationArea Of Focus
BackGlossaryArea Of FocusOur key areas of research, bucketed by disease type, biology area, or therapy type.Inflammation & ImmunologyThis Area of Focus specializes in therapies that target chronic inflammatory diseases by treating them at the molecular level, and not just by relieving symptoms.Internal MedicineThis Area of Focus specializes in therapies that target cardiovascular (heart) and metabolic diseases, which are the number one cause of death worldwide. The development of these potential therapies aim to treat or prevent disease progression and improve the quality of life for patients.OncologyThis Area of Focus specializes in therapies that target cancer.VaccinesThis Area of Focus specializes in therapies that can stop a virus or bacterium before it can infect someone. Vaccines can give your body ways to identify an infecting agent, and instructions on how to defeat it—and potentially, to avoid infecting others.Show AllInflammation & ImmunologyInternal MedicineOncologyVaccinesSubmission Type
BackGlossarySubmission TypeThe FDA, the European Medicines Agency (EMA), and other regulatory agencies around the globe have different application requirements depending on the type of investigational medicine or vaccine.New Molecular EntityA novel compound that has never been approved by a pharmaceutical regulatory agency (e.g., the FDA).Product EnhancementAn approved or investigational drug that is being tested to potentially treat another related condition. For example, drugs approved for the treatment of one type of cancer may be tested to see if they are potentially effective across another type of cancer.Show AllNew Molecular EntityProduct EnhancementCompound Type
BackGlossaryCompound TypeThe types of medicines that we’re currently developing.BiologicA type of medicine made from biological sources, such as living cells. Some of the more well-known biologics treat autoimmune conditions.Small MoleculeMedicines made from chemical compounds and manufactured by chemical synthesis. These are generally in pill form.VaccineA biological substance that stimulates an immune response against a disease. They’re usually given by injections.Show AllBiologicSmall MoleculeVaccineProject Status
BackGlossaryProject StatusDesignation of whether a project is “current” or “discontinued.”CurrentAn investigational drug or vaccine that is currently being evaluated in clinical trials.DiscontinuedWhen an investigational drug or vaccine shows an unacceptable safety/tolerability profile or lack of efficacy, or for other reasons, the clinical development program can be stopped. This entry will then be removed from the pipeline.Project AdvancedA designation of 'Project Advanced' reflects a current candidate that has progressed from one Phase of Development to another, or has entered Phase 1, since the last pipeline update.Show AllCurrentDiscontinuedProject AdvancedIndications
BackGlossaryFast TrackFast Track (U.S.) is a designation available to a product if it is intended, whether alone or in combination with one or more other drugs, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. This designation is intended to facilitate development and expedite review of drugs to treat serious and life-threatening conditions so that an approved product can reach the market expeditiously. More information about the qualifying criteria and features of the Fast Track program can be found on the FDA’s website.Breakthrough DesignationBreakthrough Designation (U.S.) may be granted to a drug (alone or in combination with 1 or more other drugs) intended to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. A drug that receives breakthrough designation is eligible for all fast-track designation features and an FDA commitment to work closely with the sponsor to ensure an efficient drug development program. More information about the qualifying criteria and features of the Breakthrough program can be found on the FDA’s website.Orphan DrugOrphan Drug (U.S.) - Orphan drug status may be granted to drugs and biologics that are intended for the diagnosis, prevention, or treatment of rare diseases/disorders that affect fewer than 200,000 people in the U.S., or that affect more than 200,000 persons but where it is unlikely that expected sales of the product would cover the sponsor’s investment in its development. More information about the qualifying criteria, features, and incentives involved in an orphan drug designation can be found on the FDA’s website.Regenerative Medicine Advanced Therapy (RMAT)Regenerative Medicine Advanced Therapy (RMAT) (U.S.) is a designation that is granted to regenerative medicine therapies intended to treat, modify, reverse, or cure a serious condition, for which preliminary clinical evidence indicates that the medicine has the potential to address an unmet medical need. The RMAT designation includes all the benefits of the fast track and breakthrough therapy designation programs, including early interactions with FDA.Rare Pediatric Disease (RPD)Rare Pediatric Disease (RPD) (U.S.) designation may be granted to a drug intended to treat a rare pediatric disease that is serious or life-threatening in which the serious or life-threatening manifestations primarily affect patients from birth to 18 years, including neonates, infants, children, and adolescents.Priority ReviewPriority Review (U.S.) A U.S. drug application will receive a priority review designation if it is for a drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. A priority designation is intended to direct overall attention and resources to the evaluation of such applications. A priority review designation means that FDA’s goal is to act on the marketing application within 6 months of receipt (compared with 10 months under standard review). More information about the qualifying criteria and features of a priority review designation can be found on the FDA’s website.Orphan Drug (E.U.)Orphan Drug (E.U.) - Orphan drug status may be granted to drugs and biologics that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting no more than 5 in 10,000 persons in the European Union at the time of submission of the designation application, or that affect more than 5 in 10,000 persons but where it is unlikely that expected sales of the product would cover the investment in its development. More information about the qualifying criteria, features, and incentives involved in an orphan drug designation can be found on the EMA’s website.PRIMEPRIME (E.U.) - The PRIME scheme is applicable to products under development which are innovative and yet to be placed on the EU market. The scheme aims to support medicinal products of major public health interest and from the viewpoint of therapeutic innovation. Medicines eligible for PRIME must address an unmet medical need, i.e., for which there exists no satisfactory method of diagnosis, prevention or treatment in the Community or, if such a method exists, in relation to which the medicinal product concerned will be of major therapeutic advantage to those affected. A product eligible for PRIME should demonstrate the potential to address, to a significant extent, the unmet medical need, for example by introducing new methods of therapy or improving existing ones. Data available to support the request for eligibility should support the claim to address the unmet medical need through a clinically meaningful improvement of efficacy, such as having an impact on the prevention, onset or duration of the condition, or improving the morbidity or mortality of the disease. EMA will provide early and enhanced support to optimize the development of eligible medicines. Products granted PRIME support are anticipated to benefit from the Accelerated Assessment procedure. More information about the qualifying criteria and features of PRIME and Accelerated Assessment can be found on the EMA’s website.Show AllFast TrackBreakthrough DesignationOrphan DrugRegenerative Medicine Advanced Therapy (RMAT)Rare Pediatric Disease (RPD)Priority ReviewOrphan Drug (E.U.)PRIMECompound Name
BackGlossaryCompound Name'Compound Name' refers to a chemical substance or molecule that is being investigated for its potential therapeutic effects, using an internal Pfizer compound number, brand name and/or generic name.Show AllAll FiltersSearchDevelopment PhasePhase 1Phase 2Phase 3RegistrationArea Of FocusInflammation & ImmunologyInternal MedicineOncologyVaccinesSubmission TypeNew Molecular EntityProduct EnhancementCompound TypeBiologicSmall MoleculeVaccineProject StatusCurrentDiscontinuedProject AdvancedBackSearch ProductsBack
result found
Development PhasePhase 1Phase 2Phase 3RegistrationArea of focusSubmission TypeCompound TypeProject StatusBackOverview
results found
results foundIndications
[H3]
[H4] Development Phase
Phase 1Phase 2Phase 3RegistrationArea of focusSubmission TypeCompound TypeProject StatusEnable Light ModePipelineas of May 5, 202635Phase 125Phase 231Phase 35Registration96TotalFiltersselect allresetDevelopment PhaseiPhase 1Phase 2Phase 3RegistrationArea Of FocusiInflammation & ImmunologyInternal MedicineOncologyVaccinesSubmission TypeiNew Molecular EntityProduct EnhancementCompound TypeiBiologicSmall MoleculeVaccineProject StatusiCurrentDiscontinuedProject Advanced
[H4]
No Search Results Found!!
Adjust filters or reset all to view products
COMPOUND NAME iINDICATION iAREA OF FOCUSiSUBMISSION TYPEiCOMPOUND TYPEiPhase 1
ABRYSVO
current
Respiratory Syncytial Virus Infection (pediatric)
Vaccines
Product Enhancement
Vaccine
Phase 1
claturafenib (PF-07799933)
current
Advanced Solid Tumors
Oncology
New Molecular Entity
Small Molecule
Phase 1
Dekavil
current
Rheumatoid Arthritis (Biologic)
Inflammation & Immunology
New Molecular Entity
Biologic
Phase 1
MET-034i +/- berobenatide (MET-097i) (PF-08654698 +/- PF-08653944)
current
Chronic Weight Management (Biologic)
Internal Medicine
New Molecular Entity
Biologic
Phase 1
MET-224o (PF-08656796)
current
Chronic Weight Management (Biologic)
Internal Medicine
New Molecular Entity
Biologic
Phase 1
MET-815i (PF-08656795)
current
Chronic Weight Management (Biologic)
Internal Medicine
New Molecular Entity
Biologic
Phase 1
PF-06835375
current
Lupus (Biologic)
Inflammation & Immunology
Product Enhancement
Bi

[H1] Use your power for purpose.

Careers Menu
CareersWho We AreJoin UsCareers in OncologyCareers in Research & DevelopmentCareers in ManufacturingCareers in Biopharma, Sales & MarketingDisability and Neurodiversity HubEarly CareersContract OpportunitiesAll Other Roles (HR, Legal, Digital...)AI Use GuidelinesLife at PfizerCareer Growth & DevelopmentHomeAboutCareers
[H1] This is where today’s pioneers, problem solvers, and pathfinders meet to create tomorrow’s breakthroughs. Together, we can transform patients’ lives.
Play Video (Opens in a new window)
[H2] Discover How You Can Make An Impact
Research & Development
[IMG: default-image]
[IMG: hover-image]
Research & Development

Manufacturing
[IMG: default-image]
[IMG: hover-image]
Manufacturing

Biopharma, Sales & Marketing
[IMG: default-image]
[IMG: hover-image]
Biopharma, Sales & Marketing

Early Careers
[IMG: default-image]
[IMG: hover-image]
Early Careers

All Other Roles
[IMG: default-image]
[IMG: hover-image]
All Other Roles

Contractor Opportunities
[IMG: default-image]
[IMG: hover-image]
Contractor Opportunities
Benefits
[IMG: Three people talking]
[H5]
Pay for Performance Philosophy and Practices

Pfizer structures its compensation policies and practices to recognize that colleagues should be rewarded based on the contributions they make to our business.
[IMG: Doctor and patient talking]
[H5]
Benefits to Maintain and Promote Health and Wellness

Depending on the customs and laws of a specific country, Pfizer offers colleagues health and wellness programs that help them maintain and promote optimum health and wellness. These programs can include health and disability insurance, preventative health programs, medical screening, free or reduced-cost vaccinations, discounts on Pfizer products, and nutrition and fitness counseling.
[IMG: Man reading papers]
[H5]
Benefits to Help Colleagues Meet Financial Goals

Depending on local custom and practice, Pfizer offers colleagues several benefits to help them meet their financial goals. These programs can include access to colleague-directed retirement funds, company contributions to retirement financial vehicles, life insurance, and financial planning education.
Button previous
Button next
[H3] Diverse perspectives help solve impossible problems.
Representation in healthcare is not just important — it’s vital. Our core values are simple and interconnected: courage, excellence, equity, and joy. These values are only possible when we ensure that all of our colleagues feel welcome to bring their full selves to work and feel included at every step of their Pfizer journey. Learn More About our Values Powered By Our People
[IMG: Image of Daniel Gilmer]
[H5]
Daniel Gilmer, New York, NY, USA, Diagnostics Launch Lead, 5 years

What is something you would tell someone who is just starting their career with Pfizer?"Given the many available opportunities, colleagues with an entrepreneurial spirit thrive at Pfizer as they build relationships that lead to their engagement on breakthrough projects with high visibility."
[IMG: Headshot of Anna Capaldi]
[H5]
Anna Capaldi, Pennsylvania, USA, Pfizer R&D Data Privacy Steward, 20 years

What is something you would tell someone who is just starting their career with Pfizer? “Pfizer aces at taking care of its people. From educational assistance to health care subsidy in retirement, Pfizer knows that its best asset are the people who work here.”
[IMG: Headshot Esteban Lepiz]
[H5]
Esteban Lepiz , Specialist, 8 years

What is something you would tell someone who is just starting their career with Pfizer?“Enjoy the journey, it is a company where you will not get bored due to its high dynamism, and you will always have many opportunities to learn new things.”
Button previous
Button next
[IMG: Two women looking at each other]
[H2] Pioneer Your Future
Success isn’t always linear, so we’re creating new ways to grow. We’ve transformed growth and development at Pfizer to ensure that everyone can follow a path to their dream career, whether that’s climbing a traditional ladder or “zig-zagging” their way to a new role. At Pfizer, you’ll lead your journey.
Learn How to Connect With Us
Details Together, We Make Pfizer A Great Place To Work
[IMG: Newsweek Logo]
[H5]
One of America's Greatest Workplaces 2023

[IMG: Fortune Logo]
[H5]
Fortune World’s Most Admired Companies All-Stars 2023

[IMG: Forbes Best Employers for New Grads Logo]
[H5]
The Best Employers for New Grads 2023

[IMG: Time World]
[H5]
World's Best Companies 2023

[IMG: Best Companies to Work for 2023-2024]
[H5]
Best Companies to Work for 2023-2024

[IMG: Newsweek Greatest Workplaces]
[H5]
America's Greatest Workplaces 2023

[IMG: Equality 100 Award]
[H5]
Equality 100 Award

Button previous
Button next
[H3] Connect With Pfizer Careers
[IMG: social media icon]
[IMG: social media icon]
[IMG: social media icon]
[IMG: social media icon]
[IMG: social media icon]
[IMG: social media icon]
Join Our Talent CommunityUS/PR RegulationsU.S. and Puerto Rico – Information required by Federal/State/Local Regulations and Other Pfizer Resources Pfizer People Experience Policies
EO and Section 503/VEVRAA Policy StatementAmericans with Disabilities Act Accommodation PolicyDiscrimination, Harassment and Retaliation Prevention Policy Equal Employment Opportunity PolicyGuidance on Religious Accommodation in the WorkplacePay Transparency Policy StatementPregnancy, Childbirth & Lactation Accommodation Guidance and Procedure Federal Government Posters
Employee Polygraph Protection Act PosterEmployee Rights under the FMLAKnow your Rights: Workplace Discrimination is IllegalRight to Work Additional Information (By State)
New YorkNew York City Automated Employment Decision Tools (AEDT) Notice and Annual ReportPfizer endeavors to make www.pfizer.com/careers accessible to all users. If you would like to contact us regarding the accessibility of our website or need assistance completing the application process and/or interviewing, please email [email protected]. This is to be used solely for accommodation requests with respect to the accessibility of our website, online application process and/or interviewing.  Requests for any other reason will not be returned.

HomeContact Us
[H1] Contact Us
[H2] Contact Us
[H4] Thank you for your interest in Pfizer. Please know that we read all the messages sent to us. However, due to the large volume of messages we receive, you may not get a personal reply. Please note, fields marked with an asterisk (*) are required to be filled out.
Medical Information Contacts
Use the dropdown menu to select your location.
[IMG: hand holding up globe of the world]
[H2] Call Us
Customer Service and Product Inquiries:1-800-879-3477 Monday through Friday 9:00 a.m. to 7:00 p.m. ESTPfizer Inc.
66 Hudson Boulevard East
New York, NY 10001-2192 USAThe answer to your question may be just a click away. So, you may want to take a look at our most frequently asked questions and answers before contacting us. Get the Answers to Your Questions If you experience any unexpected side effects from one of our drugs, first tell your healthcare provider and then report it to us. This helps us track the safety of our medicines with more accuracy.Report Adverse EffectsIf you are a journalist researching Pfizer, you may contact us directly.Contact a Media Representative
[H2] SSN Protection Policy
In the ordinary course of business, sometimes we have to collect your Social Security number to fulfill legal or regulatory obligations, or for other administrative purposes. It is our policy to avoid the unnecessary collection of Social Security numbers. We limit access to your Social Security number in order to protect your privacy  and to prohibit the unlawful disclosure of your Social Security number.
[H2] Keeping Our Systems Secure
We take cybersecurity seriously, and value the contributions of the security community at large. The responsible disclosure of potential issues helps us to ensure the security and privacy of our customers and data. If you believe you have found a security issue in one of our products or services, please let us know through our Responsible Disclosure Policy.

[IMG: banner]
[H1] Partners: Teaming up for Breakthroughs
Partnerships can save lives. We’re eager to work with innovators who share our values and our focus.HomeAboutPartnersResearch and Business Development Partnerships
[H2] Research and Business Development Partnerships
[H4] Pfizer is proud of its long history of successfully partnering with external organizations that share in our purpose to deliver breakthroughs that change patients’ lives.
We engage in partnerships with innovators to push forward great science and continually seek new partners that are actively researching bold scientific ideas, capabilities and technologies that have the potential to bring innovative treatments to patients in need. Pfizer has several key areas of interest where we are looking to partner with others. Select an area below to see where we are focusing our partnering efforts.
[H4] Scientific Areas of Focus
Select an area below to see where we are focusing our partnering efforts.
[H3] Therapeutic Areas
Hospital
Pfizer’s Hospital medicines reach patients at virtually every stage of life. The depth and breadth of our portfolio of trusted medicines and capabilities, and our presence in 160 countries, enables us to deliver value to patients throughout the world.We are proud to provide access to our quality medicines to healthcare systems and patients in both developing and emerging markets. Pfizer’s Hospital medicines currently offers one of the industry’s largest and most diverse portfolios of anti-infectives and we’re a leader in sterile injectable manufacturing worldwide including the emerging markets.Strategic Areas of Interest Pfizer’s Hospital medicines reach patients at virtually every stage of life. The depth and breadth of our portfolio of trusted medicines and capabilities, and our presence in 160 countries, enables us to deliver value to patients throughout the world.We are proud to provide access to our quality medicines to healthcare systems and patients in both developing and emerging markets. Pfizer’s Hospital medicines currently offers one of the industry’s largest and most diverse portfolios of anti-infectives and we’re a leader in sterile injectable manufacturing worldwide including the emerging markets. Inflammation and Immunology
Pfizer is a global leader in discovering and developing medicines for patients suffering from chronic immune diseases. Pfizer is committed to the discovery and development of novel therapeutics to help patients living with immune-inflammatory diseases. Pfizer Inflammation & Immunology is focused on discovering and developing the next generation of therapies for immune- mediated diseases. Pfizer is interested in entering into strategic relationships with innovative collaborators to develop novel and differentiated therapies for autoimmune diseases.We are interested in establishing alliances to develop therapeutics, expand disease biology understanding, and identify biomarkers that impact three main areas:Rheumatology
Rheumatoid ArthritisSystemic / Cutaneous Lupus ErythematosusLupus NephritisScleroderma, localized and systemicSystemic SclerosisMyositisSjögren's SyndromeVasculitisGiant Cell ArteritisRare rheumatologic diseasesSpondyloarthropathiesGastroenterology/Hepatology
Inflammatory Bowel DiseaseF4 Non-Alcoholic SteatohepatitisFibrosing / Stricturing Crohn’s DiseaseAutoimmune HepatitisRefractory CeliacEosinophilic EsophagitisSystemic aspects of food allergyMedical Dermatology
Atopic DermatitisAlopecia AreataVitiligoHidradenitis SuppurativaChronic Spontaneous UrticariaPruritis indications: Lichen Sclerosus, Seborrheic / Perioral Dermatitis, Chronic Hand Eczema, Prurigo NodularisBullous Pemphigoid,Pemphigus VulgarisNon-GI/Hepatology Fibrotic DiseasesOther indications with high unmet need that are related to those aboveSpecific areas of interest include:Cytokines and their signaling pathwaysAdaptive Immunity, Lymphocyte biology including Th17 lymphocytesRegulatory cells and Tolerance inductionHost-microbial interactions and microbiome with an interest in epithelial barrierLeukocyte metabolismInnate Immunity and Innate Lymphoid Cell biologyOxidative stress modulatorsPan anti-fibroticsNovel methods to target pathogenic inflammatory fibroblast populationsTechnology platforms and products to help understand patient segmentation in the disease areas of interest and develop precision medicine strategies for innovative portfolio productsTechnology platforms and products that allow for greater tissue and cell specific deliveryNot actively seeking partnering opportunities in:TNFα, IL-1ß targeting biologicsB cell depleting biologicsCorticosteroids Internal Medicine
Cardiovascular diseases (CVD) remain the leading cause of global mortality, accounting for one in every two adult deaths worldwide. The rates of CVD-related morbidity, including heart-failure, peripheral arterial disease and nephropathy are increasing as more patients survive hearts attacks, and the population ages. In addition, Metabolic Diseases, specifically Type 2 diabetes (T2D) and obesity, are major health problems that have reached epidemic proportions worldwide. Globally T2D and obesity incidence have more than doubled in the past two decades. Importantly, CVD and T2D impose large economic burdens on the individual patient and on national healthcare systems and economies. Pfizer scientists are eager to work with world-class partners who share our mission to develop novel and differentiated medicines to improve the lives of patients suffering from CVD.Pfizer is interested in partnering to develop therapeutics, expand our understanding of disease biology, and identify biomarkers that can help us impact: CVD (Heart failure, hypertriglyceridemia, atherosclerosis)Type 2 diabetes and related disorders such as hyperinsulinemiaNon-alcoholic fatty liver disease (NAFLD), Non-alcoholic steatohepatitis (NASH), and liver cirrhosisCachexia as a consequence of chronic illnessObesity and related co-morbiditiesChronic kidney disease, diabetic kidney disease, and polycystic kidney diseaseVascular diseaseSpecific areas of interest include: Metabolic treatments of heart failure (HFrEF, HFpEF)Novel therapies that target insulin sensitivity in type 2 diabetesAddressing obesity and eating disorders to induce and sustain weight lossNew mechanisms and pathways for the treatment of diabetic nephropathy, chronic kidney disease or polycystic kidney diseaseNovel approaches to target vascular dysfunctionNot actively seeking partnering opportunities in: Anti-arrhythmicsStable angina treatments Oncology
Pfizer Oncology strives to advance the frontiers of cancer biology and to translate this knowledge into high-impact medicines for cancer patients. Our core areas of interest include: Tumor Cell Biology; Precision Medicine; Tumor Targeted Therapeutics; and Immuno-Oncology. In addition, our Integrative Biotechnology Group supports novel target identification and validation through functional genomics, proteomics, and other “omic” approaches.We are interested in establishing alliances to develop therapeutics, expand disease biology understanding, and identify biomarkers that impact:Breast, prostate, lung, bladder, colorectal, renal, melanoma and hematologic cancersSpecific areas of interest include:Oncogenic drivers and signaling pathwaysEpigeneticsHormone signalingSynthetic lethalitySelective protein degradersTranscriptional regulatorsImmune modulatorsImmune cell engagersPrecision medicineFunctional genomicsLiquid biopsy and imaging technologiesIn vivo cell reprogrammingImmuno-OncologyThe clinical successes reported with cancer immunotherapy are reshaping the field of oncology. Pfizer is significantly advancing activity in this area by partnering todevelop cutting edge science beyond the current mainstream immune checkpoints. The IO programs at Pfizer uniquely leverage a combination of our scientific and clinical strength in immunobiology, as well as our historical expertise in developing first-in-class cancer therapies.Pfizer’s efforts in IO include external collaborative alliances with leading academic medical centers and visionary biotech firms. Our IO efforts are driven primarily by the Cancer Immunology Discovery Unit (CID) within our La Jolla, CA-based laboratory site. Leveraging its strength in biotherapeutics, along with core expertise in immunobiology, CID has a strong record of converting validated targets into novel protein-based therapeutics and advancing molecular and cell-based IO treatments. We would like to partner in the IO space on pre-clinical and clinical-stage immunomodulatory opportunities, with an emphasis on those agents that directly engage or impact T-cell and other tumor-infiltrating immune cell populations.We are interested in establishing alliances to develop and access:Novel Targets for Overcoming Tumor-associated Immune Resistance
Targets that impact the immune response to cancer cells; innate immune activation; and immuno-suppressionPlatform Technologies
Mechanisms, biomarkers, and screening approaches to identify and accelerate the most promising combination therapiesNew modalities to promote immune responses: Bi-specific and Tri-specific antibody/cytokine platforms, nanoparticles, or novel T cell receptors (TCRs)Identification of new immune-modulating targetsMonitoring of biomarkers of immune-responsiveness and immune-suppression within tumorsNovel animal models that recapitulate more faithfully human tumor-immune system interactionsNot actively seeking partnering opportunities in:Antisense/siRNA/shRNA therapeuticsReformulated cytotoxic agents Rare Diseases
With the vision to be a leader in the development of therapeutic solutions for Rare Diseases, we have focused our business development strategy to align with the Category’s objective to identify and prioritize collaborations and partnerships to advance therapies for rare diseases where there remains high unmet need. Pfizer has adopted an innovative and collaborative approach to the development of new medicines for patients with rare diseases. We have a track record of creating innovative strategic partnerships with academic institutions, patient advocacy groups, and commercial enterprises to accelerate the development of novel therapeutics across a wide spectrum of rare diseases. Our expertise in small and large molecule therapeutics, and genetic therapies has resulted in a broad pipeline of potentially transformative medicines across four primary therapeutic areas, namely rare hematology, neurology, renal, cardiology and metabolic diseases. Therefore, we are seeking new business opportunities that span these disease indications and are not limited by molecule type.Pfizer is interested in partnering to develop therapeutics, expanding our understanding of disease biology, and identifying biomarkers that can help us impact:Rare renal and cardiac diseasesRare endocrinology & metabolic diseasesRare neurologic diseasesRare hematologic diseasesGenetic-based approaches (e.g., gene therapy and gene editing) in the above disease areasSpecific areas of interest include:Gene therapy-, gene editing-, and mRNA-based therapies including methods to minimize host immune responses and afford redosing with viral vectorsOral small molecule- and biologics-based approachesModifiers of expanded repeat disordersPharmacologic chaperones and other modifiers of protein trafficking, misfolding, or degradation that could be applied to multiple diseasesNot actively seeking partnering opportunities in:DermatologyRare oncologyEx-vivo gene therapies Vaccines
Vaccines are one of the greatest public health advancements of all time, resulting in the control, elimination, or near-elimination of numerous infectious diseases that were once pervasive and often fatal. Pfizer has a rich history in vaccine research and development. Over the years, we’ve played a pivotal role in eliminating or nearly eliminating deadly infectious diseases like smallpox and polio globally. We have designed novel vaccines based on new delivery systems and technologies that have resulted in vaccines to prevent bacterial infections, like those caused by S. pneumoniae and N. meningitidis.Today, more people are benefiting from safe and efficacious vaccines to prevent infectious diseases than ever before, and vaccines provide essential health benefits at all ages, from maternal and infant populations to seniors. However, our work is not done given the many infectious diseases with high unmet medical need as well as the existence of a growing number of diseases which are potentially vaccine- preventable.It is an exciting time in vaccine research and development, as scientific discoveries, technological advancements and regulatory paradigms are paving the way for novel vaccines. While Pfizer’s Vaccine Research and Development scientists continue to extend our leadership position in pneumococcal and meningococcal disease prevention, they are also working on vaccines against other major infectious diseases while striving to bring the benefits of vaccines into previously unexplored areas. We are at the forefront to usher in a new era of vaccine innovation, to prevent serious infectious diseases that span our life span, protecting infants through maternal immunization and infant immunization through to older adults.The approval of the first mRNA-based COVID-19 vaccines was a scientific turning point, establishing mRNA as a versatile, flexible technology. The focus and drive Pfizer exhibited in developing our COVID-19 vaccine in partnership with BioNTech produced a wealth of scientific knowledge in just one year.Pfizer’s next wave of mRNA scientific innovation is expanding in the infectious disease arena with development programs in influenza and shingles, and we are also exploring the application of mRNA technology in other areas, including in rare genetic diseases. Our intention is to evaluate opportunities where the scientific rationale for using mRNA technology along with Pfizer’s expertise in disease is strongest, and where the potential impact on patients could be the greatest.Pfizer Vaccines is interested in partnering opportunities in Vaccines R&D:Infectious disease vaccines that address a high unmet medical need and represent a breakthrough vs. standard of careFocus on bacterial and viral vaccinesSpecific areas of interest in Vaccine Research include:Research tools, reagents, and materials to aid in vaccine discoveryNovel viral and bacterial antigens (peptides, proteins, DNA, RNA, glycoconjugates) and expression systemsImmunomodulators, adjuvants, delivery platforms, and vector systems to enhance vaccine immune responsesNeedle-free alternative delivery methods and devicesBroad platform technologies for application across multiple programs
[H3] Therapeutic Modalities and Technology Platforms
Medicine Design
We are interested in establishing alliances to develop and access novel:Medicinal Chemistry Synthesis TechnologySy